BEIGENE Shares Surge Over 4% on Positive Phase 3 Clinical Trial News for Zanubrutinib

Stock News07-03

Shares of BEIGENE (HKEX: 06160) rose more than 4% in early trading. At the time of writing, the stock was up 4.58% to HK$182.7, with a turnover of HK$81.56 million.

The increase follows the company's announcement of positive results from its MANGROVE Phase 3 clinical study (BGB-3111-306; NCT04002297). This global, randomized trial evaluated the company's foundational, self-developed BTK inhibitor, Brukinsa (zanubrutinib), in combination with rituximab, compared to the standard immunochemotherapy regimen of bendamustine plus rituximab (BR), for the first-line treatment of adult patients with mantle cell lymphoma (MCL).

MANGROVE is the first global Phase 3 study to assess a chemotherapy-free regimen based on a BTK inhibitor against standard immunochemotherapy in this treatment setting. The positive outcome from this pivotal trial is expected to strengthen the clinical evidence base for zanubrutinib in the MCL disease area.

The company plans to present the full results from the MANGROVE study at an upcoming medical conference. BEIGENE is also engaging with global regulatory authorities regarding the registration submission plan, with an aim to file for approval in the second half of 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163772490?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163772490","market":"sh","top_or_hot":-1,"title":"BEIGENE Shares Surge Over 4% on Positive Phase 3 Clinical Trial News for Zanubrutinib","media":"Stock News","content":"<p>Shares of <b>BEIGENE</b> (<b>HKEX: 06160</b>) rose more than 4% in early trading. At the time of writing, the stock was up 4.58% to HK$182.7, with a turnover of HK$81.56 million.<br><br>The increase follows the company's announcement of positive results from its MANGROVE Phase 3 clinical study (BGB-3111-306; NCT04002297). This global, randomized trial evaluated the company's foundational, self-developed BTK inhibitor, Brukinsa (zanubrutinib), in combination with rituximab, compared to the standard immunochemotherapy regimen of bendamustine plus rituximab (BR), for the first-line treatment of adult patients with mantle cell lymphoma (MCL).<br><br>MANGROVE is the first global Phase 3 study to assess a chemotherapy-free regimen based on a BTK inhibitor against standard immunochemotherapy in this treatment setting. The positive outcome from this pivotal trial is expected to strengthen the clinical evidence base for zanubrutinib in the MCL disease area.<br><br>The company plans to present the full results from the MANGROVE study at an upcoming medical conference. <b>BEIGENE</b> is also engaging with global regulatory authorities regarding the registration submission plan, with an aim to file for approval in the second half of 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BEIGENE Shares Surge Over 4% on Positive Phase 3 Clinical Trial News for Zanubrutinib</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBEIGENE Shares Surge Over 4% on Positive Phase 3 Clinical Trial News for Zanubrutinib\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-03 09:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>BEIGENE</b> (<b>HKEX: 06160</b>) rose more than 4% in early trading. At the time of writing, the stock was up 4.58% to HK$182.7, with a turnover of HK$81.56 million.<br><br>The increase follows the company's announcement of positive results from its MANGROVE Phase 3 clinical study (BGB-3111-306; NCT04002297). This global, randomized trial evaluated the company's foundational, self-developed BTK inhibitor, Brukinsa (zanubrutinib), in combination with rituximab, compared to the standard immunochemotherapy regimen of bendamustine plus rituximab (BR), for the first-line treatment of adult patients with mantle cell lymphoma (MCL).<br><br>MANGROVE is the first global Phase 3 study to assess a chemotherapy-free regimen based on a BTK inhibitor against standard immunochemotherapy in this treatment setting. The positive outcome from this pivotal trial is expected to strengthen the clinical evidence base for zanubrutinib in the MCL disease area.<br><br>The company plans to present the full results from the MANGROVE study at an upcoming medical conference. <b>BEIGENE</b> is also engaging with global regulatory authorities regarding the registration submission plan, with an aim to file for approval in the second half of 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4526","symbol_name":"热门中概股","start_time":0,"source_url":"","article_id":"1163772490","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163772490","pubTimestamp":1783042997,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of BEIGENE (HKEX: 06160) rose more than 4% in early trading. At the time of writing, the stock was up 4.58% to HK$182.7, with a turnover of HK$81.56 million.The increase follows the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688235":"百济神州","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK4139":"生物科技","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK1583":"高瓴概念","BK0239":"医药制造","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK4588":"碎股","ONC":"百济神州","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","BK1500":"做空集合股","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","06160":"百济神州","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","BK1161":"生物科技","BK1588":"回港中概股","VXUS":"国际股票ETF-Vanguard","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC"},"translate_title":"泽布替尼3期临床试验消息利好，百济神州股价飙升逾4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688235":1,"ONC":1,"VXUS":1,"06160":1},"content_text":"Shares of BEIGENE (HKEX: 06160) rose more than 4% in early trading. At the time of writing, the stock was up 4.58% to HK$182.7, with a turnover of HK$81.56 million.The increase follows the company's announcement of positive results from its MANGROVE Phase 3 clinical study (BGB-3111-306; NCT04002297). This global, randomized trial evaluated the company's foundational, self-developed BTK inhibitor, Brukinsa (zanubrutinib), in combination with rituximab, compared to the standard immunochemotherapy regimen of bendamustine plus rituximab (BR), for the first-line treatment of adult patients with mantle cell lymphoma (MCL).MANGROVE is the first global Phase 3 study to assess a chemotherapy-free regimen based on a BTK inhibitor against standard immunochemotherapy in this treatment setting. The positive outcome from this pivotal trial is expected to strengthen the clinical evidence base for zanubrutinib in the MCL disease area.The company plans to present the full results from the MANGROVE study at an upcoming medical conference. BEIGENE is also engaging with global regulatory authorities regarding the registration submission plan, with an aim to file for approval in the second half of 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163772490","isCrawlerRequest":true}